The Cooperative Ovarian Cancer Group for Immunotherapy (COGI), based
at Stanford University, is a consortium of ovarian cancer researchers
from 22 leading academic medical centers throughout the United States
and United Kingdom, including Stanford University, Harvard University,
Memorial Sloan Kettering Cancer Center, University of Pennsylvania, and
the University of Washington. This group was formed in 2004 to focus
on the development of vaccines and innovative immunotherapies for ovarian
cancer.
Ten institutions are full COGI members and 29 institutions are affiliates.
Since its inception, COGI has met annually as a group to plan strategy,
and has supported laboratory programs, each of which will initiate a
clinical vaccine trial directed for ovarian cancer.
The overall strategy and aims of COGI are to:
- Develop a strong Core Program that coordinates a network of clinical
investigators who are dedicated to the conduct of innovative
clinical trials of vaccines and immunotherapies in ovarian cancer.
- Support
and facilitate basic laboratory investigations that are designed
to translate to clinical trials of ovarian cancer vaccines.
- Create partnerships with biotech industry that will support and
utilize our group to conduct meaningful trials and perform
correlative assays to study the mechanism of action of the therapies.
- Recruit
additional funding to expand our programs and to enable sustained
funding beyond our granting period.
COGI
is led by group principal investigator, Dr.
Jonathan Berek, Professor and Chair, Department of Obstetrics and
Gynecology, Stanford University School of Medicine, and the Division
of Gynecologic Oncology, Stanford Cancer CenterCentral management of
this organization is performed by Stanford University personnel, led
by COGI Program Coordinator, Colleen
Fitzsimmons. (left)
This consortium includes key research laboritories at the University
of Pennsylvania, directed by George
Coukos, MD, PhD; and at the Univerisity of Washington, led by Nora
Disis, PhD.